Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study-Reference-Cited by-同舟云学术

Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study

Published:2018-06 Issue:6 Volume:113 Page:890-898
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Ungar Bella,Engel Tal,Yablecovitch Doron,Lahat Adi,Lang Alon,Avidan Benjamin,Har-Noy Ofir,Carter Dan,Levhar Nina,Selinger Limor,Neuman Sandra,Natour Ola Haj,Yavzori Miri,Fudim Ella,Picard Orit,Kopylov Uri,Chowers Yehuda,Naftali Timna,Broide Efrat,Shachar Eyal,Eliakim Rami,Ben-Horin Shomron

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/s41395-018-0073-0.pdf

Reference33 articles.

1. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohns disease.;Karmiris;Gastroenterology,2009

2. Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohns disease and ulcerative colitis.;Yarur;Inflamm Bowel Dis,2016

3. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohns disease.;Mazor;Aliment Pharmacol Ther,2014

4. Antibodies to adalimumab are associated with future inflammation in Crohns patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial.;Baert;Gut,2016

5. Serum adalimumab concentration and clinical remission in patients with Crohns disease.;Chiu;Inflamm Bowel Dis,2013

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamics and implications of anti-drug antibodies against adalimumab using ultra-sensitive and highly drug-tolerant assays;Frontiers in Immunology;2024-08-22

2. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

3. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

4. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05

5. Higher Adalimumab Concentration is Associated with Complete Fistula Healing in Patients with Perianal Fistulizing Crohn’s Disease;Clinical Gastroenterology and Hepatology;2024-04